[Metastatic prostate cancer]

Rev Prat. 2003 Dec 31;53(20):2258-62.
[Article in French]

Abstract

Metastatic prostate cancer is an uncurable disease. Treatment is only palliative. Median survival of patients is 3 years. Prostate cancer is an hormonodependent cancer, androgen blockade is the most active treatment. However hormone resistance occurs after a median interval of 2 years. The major symptom is pain, others are urinary obstruction, neurological complications of bone metastases and hematological disorders. Androgen deprivation is the first-line treatment, impotency and osteoporosis being the main side effects. Other treatments are radiotherapy, radiopharmaceutics and chemotherapy. The most important treatment issue is quality of life.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use
  • Bone Neoplasms / secondary
  • Brachytherapy
  • Erectile Dysfunction / chemically induced
  • Humans
  • Male
  • Neoplasm Metastasis
  • Osteoporosis / chemically induced
  • Palliative Care
  • Prognosis
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / therapy*
  • Quality of Life
  • Time Factors

Substances

  • Androgen Antagonists